Shanghai Junshi Biosciences Co., Ltd.
SSE:688180.SS
35.75 (CNY) • At close June 16, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,948.317 | 1,502.55 | 1,453.493 | 4,024.841 | 1,594.897 | 775.089 | 0.934 | 1.148 | 3.757 | 2.887 | 5.802 |
| Cost of Revenue
| 498.861 | 667.29 | 526.282 | 1,258.187 | 372.531 | 90.684 | 0.267 | 0.446 | 0.986 | 0.133 | 3.688 |
| Gross Profit
| 1,449.456 | 835.26 | 927.211 | 2,766.654 | 1,222.366 | 684.405 | 0.667 | 0.702 | 2.771 | 2.754 | 2.113 |
| Gross Profit Ratio
| 0.744 | 0.556 | 0.638 | 0.687 | 0.766 | 0.883 | 0.714 | 0.611 | 0.738 | 0.954 | 0.364 |
| Reseach & Development Expenses
| 1,275.27 | 1,937.47 | 2,384.373 | 2,068.739 | 1,778.023 | 946.1 | 538.183 | 275.303 | 122.001 | 0 | 29.688 |
| General & Administrative Expenses
| 547.713 | 556.808 | 578.269 | 647.95 | 443.346 | 244.229 | 124.837 | 73.752 | 42.76 | 83.846 | 42.834 |
| Selling & Marketing Expenses
| 984.554 | 844.356 | 715.704 | 734.563 | 687.971 | 320.056 | 20.304 | 0 | 0 | 0 | 1.565 |
| SG&A
| 1,532.267 | 1,401.164 | 1,293.973 | 1,382.513 | 1,131.317 | 564.285 | 145.141 | 73.752 | 42.76 | 83.846 | 44.399 |
| Other Expenses
| -57.879 | -51.358 | -34.189 | -91.891 | -18.556 | -31.546 | 17.022 | 47.42 | -13.68 | 0 | 0 |
| Operating Expenses
| 2,749.658 | 3,287.276 | 3,644.157 | 3,359.361 | 2,890.784 | 1,478.839 | 684.79 | 346.441 | 151.081 | 74.816 | 37.788 |
| Operating Income
| -1,300.202 | -2,452.016 | -2,671.626 | -685.331 | -1,679.078 | -764.444 | -684.123 | -345.739 | -148.31 | -81.092 | -42.286 |
| Operating Income Ratio
| -0.667 | -1.632 | -1.838 | -0.17 | -1.053 | -0.986 | -732.466 | -301.166 | -39.476 | -28.091 | -7.288 |
| Total Other Income Expenses Net
| -22.329 | -37.871 | -3.576 | -2.293 | -0.206 | -25.206 | -33.59 | 24.995 | 17.061 | 22.352 | 2.664 |
| Income Before Tax
| -1,322.531 | -2,489.887 | -2,675.202 | -592.648 | -1,669.461 | -763.124 | -717.713 | -320.744 | -131.249 | -58.74 | -24.479 |
| Income Before Tax Ratio
| -0.679 | -1.657 | -1.841 | -0.147 | -1.047 | -0.985 | -768.429 | -279.394 | -34.935 | -20.348 | -4.219 |
| Income Tax Expense
| 22.552 | 43.995 | -93.107 | 135.533 | -3.822 | -18.891 | -1.213 | 0.058 | 0.241 | 0.77 | 0.775 |
| Net Income
| -1,282.398 | -2,281.624 | -2,582.095 | -728.181 | -1,665.639 | -744.233 | -716.414 | -321.071 | -131.967 | -57.97 | -25.254 |
| Net Income Ratio
| -0.658 | -1.519 | -1.776 | -0.181 | -1.044 | -0.96 | -767.039 | -279.679 | -35.126 | -20.081 | -4.353 |
| EPS
| -1.3 | -2.32 | -2.81 | -0.82 | -1.91 | -0.95 | -1.19 | -0.42 | -0.17 | -0.26 | -0.12 |
| EPS Diluted
| -1.3 | -2.32 | -2.81 | -0.82 | -1.91 | -0.95 | -1.19 | -0.42 | -0.17 | -0.26 | -0.12 |
| EBITDA
| -1,023.801 | -2,157.661 | -2,280.401 | -259.22 | -1,484.503 | -687.258 | -686.145 | -298.33 | -122.661 | -73.974 | -39.332 |
| EBITDA Ratio
| -0.525 | -1.436 | -1.569 | -0.064 | -0.931 | -0.887 | -734.631 | -259.869 | -32.649 | -25.625 | -6.779 |